Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DESFLURANE vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Induction of anesthesia in adults and pediatric patients
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Minimal hepatic metabolism (<0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Approximately 5–10% bound to plasma proteins (primarily albumin).
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Vd approximately 0.2–0.5 L/kg (small, reflecting limited tissue distribution; consistent with lipophilic but rapidly equilibrating profile).
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Inhalation: ~100% bioavailable into systemic circulation via lungs.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
No dosage adjustment required for renal impairment; desflurane is minimally metabolized and not dependent on renal excretion.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential for increased hepatotoxicity, but no dose modification guidelines exist.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Induction: 3-12% inhaled (up to 18% for mask induction); maintenance: 3-6% inhaled; adjust based on age and response; higher MAC requirements in infants.
Safety and efficacy not established in pediatric patients (<18 years).
Reduce dose by 20-30% compared to younger adults; typical maintenance 2-5% inhaled; lower MAC (approx 4.5% at 65 years); monitor for hypotension and bradycardia.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
Desflurane is not indicated for induction of general anesthesia in pediatric patients due to a high incidence of laryngospasm and upper airway adverse events.
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Malignant hyperthermia,Respiratory depression and airway complications,Cardiovascular depression (hypotension, bradycardia),QT prolongation,Hepatotoxicity (rare),Rising carbon monoxide levels with dry absorbents,Neurotoxicity in pediatric patients,Renal toxicity (rare)
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Known sensitivity to desflurane or other halogenated anesthetics,History of malignant hyperthermia,Refractory hypovolemia,Increased intracranial pressure (relative),Concomitant use with adrenergic agents (risk of arrhythmias)
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
No known food interactions. However, patients should follow preoperative fasting guidelines (nil per os for at least 2 hours for clear liquids and 6-8 hours for solid foods) to reduce the risk of pulmonary aspiration during anesthesia.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal heart rate variability, and neonatal respiratory depression. It is pregnancy category B, but caution is advised.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Desflurane is minimally excreted into breast milk; M/P ratio is unknown. It is considered compatible with breastfeeding due to rapid elimination from the mother and low oral bioavailability in the infant. However, monitor for neonatal sedation.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
No specific dose adjustment for desflurane in pregnancy, but the minimum alveolar concentration (MAC) is reduced by approximately 25-40% due to increased progesterone and other factors. Lower doses may be required to achieve desired anesthetic depth.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Desflurane has the lowest blood-gas partition coefficient among volatile anesthetics, resulting in the fastest onset and emergence. Its pungent odor limits use for inhalation induction, especially in children. Due to its high vapor pressure, a specialized heated vaporizer is required. Desflurane can cause sympathetic nervous system activation at high concentrations, leading to tachycardia and hypertension. It is metabolized minimally (0.02%), but can produce carbon monoxide when exposed to dried CO2 absorbents; desiccated absorbents should be avoided. Malignant hyperthermia risk is present, so dantrolene should be available.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
You will receive desflurane gas through a mask or breathing tube to keep you asleep during surgery.,Desflurane has a strong smell; you may notice an odor as you fall asleep.,You will wake up quickly after the anesthetic is stopped, but you may feel drowsy or confused initially.,Potential side effects include nausea, vomiting, shivering, and a temporary increase in heart rate or blood pressure.,Inform your doctor if you have a personal or family history of malignant hyperthermia (a severe reaction to anesthesia).,Do not eat or drink before surgery as instructed to prevent aspiration.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
"Concurrent use of buspirone and desflurane may potentiate the hypotensive and bradycardic effects of desflurane, increasing the risk of hemodynamic instability during anesthesia induction or maintenance. Buspirone's serotonergic activity can also lower seizure threshold, potentially interacting with the anesthetic properties of desflurane to cause perioperative seizures or arrhythmias. Clinically, this combination requires careful cardiovascular monitoring and dose adjustment of desflurane to avoid excessive hypotension, bradycardia, or delayed emergence."
"Concomitant use of Desflurane and Triprolidine may lead to enhanced central nervous system (CNS) depression and potential respiratory compromise. Desflurane, a volatile anesthetic, depresses the CNS and respiratory drive, while Triprolidine, a first-generation antihistamine, adds sedative and anticholinergic effects. This synergistic interaction increases the risk of excessive sedation, hypotension, and respiratory depression, particularly during induction or recovery from anesthesia. Clinically, patients may experience prolonged emergence, worsened cognitive function, and increased need for ventilatory support."
"Concomitant administration of desflurane, a volatile halogenated anesthetic, with oxprenolol, a non-selective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity, can lead to additive negative inotropic and chronotropic effects on the myocardium, resulting in significant hypotension and bradycardia. This interaction occurs because desflurane depresses myocardial contractility and heart rate directly, while oxprenolol blocks compensatory sympathetic responses, potentially compromising cardiac output and tissue perfusion. Clinicians should be vigilant for exaggerated cardiovascular depression, especially during induction or changes in anesthetic depth."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DESFLURANE vs ARAKODA, answered by our medical review team.
DESFLURANE is a General Anesthetic that works by Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DESFLURANE and ARAKODA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DESFLURANE is: Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DESFLURANE and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DESFLURANE is classified as Category C. Desflurane is not associated with major congenital malformations in the first trimester, but use in the second and third trimesters may cause fetal depression, decreased fetal hear. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.